Illumina Inc. (NASDAQ:ILMN) – Stock analysts at Cantor Fitzgerald dropped their FY2016 earnings estimates for shares of Illumina in a research note issued on Wednesday. Cantor Fitzgerald analyst B. Brokmeier now anticipates that the brokerage will earn $3.35 per share for the year, down from their prior forecast of $3.56. Cantor Fitzgerald has a “Hold” rating and a $155.00 price target on the stock.
Several other equities analysts have also recently weighed in on the company. Argus reaffirmed a “buy” rating and set a $170.00 target price (down previously from $205.00) on shares of Illumina in a research note on Friday. Cowen and Company reaffirmed an “outperform” rating and set a $160.00 target price on shares of Illumina in a research note on Wednesday. Wells Fargo & Co. reaffirmed a “market perform” rating and set a $137.50 target price (down previously from $150.00) on shares of Illumina in a research note on Wednesday. BTIG Research reaffirmed a “neutral” rating on shares of Illumina in a research note on Wednesday. Finally, Vetr raised Illumina from a “hold” rating to a “strong-buy” rating and set a $165.56 price target for the company in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $156.88.
Illumina (NASDAQ:ILMN) traded up 0.01% during mid-day trading on Friday, hitting $137.19. 797,845 shares of the stock were exchanged. The company has a 50 day moving average price of $172.04 and a 200 day moving average price of $156.15. The stock has a market cap of $20.11 billion, a price-to-earnings ratio of 46.98 and a beta of 0.47. Illumina has a 52 week low of $127.10 and a 52 week high of $196.47.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.13. The company had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The business’s quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.80 earnings per share.
A number of institutional investors have recently added to or reduced their stakes in ILMN. National Pension Service raised its position in Illumina by 8.6% in the third quarter. National Pension Service now owns 106,584 shares of the life sciences company’s stock valued at $19,362,000 after buying an additional 8,485 shares during the last quarter. Private Trust Co. NA bought a new position in Illumina during the third quarter valued at $232,000. Gulf International Bank UK Ltd raised its position in Illumina by 0.8% in the third quarter. Gulf International Bank UK Ltd now owns 44,340 shares of the life sciences company’s stock valued at $8,054,000 after buying an additional 350 shares during the last quarter. Patten & Patten Inc. TN bought a new position in Illumina during the third quarter valued at $211,000. Finally, Fox Run Management L.L.C. bought a new position in Illumina during the third quarter valued at $509,000. 95.22% of the stock is currently owned by hedge funds and other institutional investors.
In other Illumina news, Director Jay T. Flatley sold 10,000 shares of the stock in a transaction dated Monday, July 18th. The stock was sold at an average price of $150.00, for a total value of $1,500,000.00. Following the transaction, the director now owns 498,061 shares of the company’s stock, valued at $74,709,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Bradbury sold 600 shares of the stock in a transaction dated Friday, October 7th. The shares were sold at an average price of $184.36, for a total value of $110,616.00. Following the completion of the transaction, the director now directly owns 17,065 shares in the company, valued at approximately $3,146,103.40. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.